Market Research Logo

Behavioral Disorders Drug Development Pipeline Review, 2017

Behavioral Disorders Drug Development Pipeline Review, 2017

Summary

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child’s sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. There are a total of 41 products in development for this indication, by 34 companies and 4 academic institutions. Key companies operating in this pipeline space include Addex Therapeutics, Confluence Pharmaceuticals and Immuron.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. There are a total of 8 products in development for this indication by 7 companies. Key companies operating in this pipeline space include Addex Therapeutics, Abbvie, Omeros and Phytecs.

Finally, attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 58 products in development for this indication, by 41 companies and 5 academic institutions. Key companies operating in this pipeline space include NLS Pharma, Aevi Genomic Medicine, Shire and Highland Therapeutics.

Across all three of these indications, transporters and receptors of neurotransmitters such as dopamine, glutamine and serotonin, plus G protein-coupled receptors and ion channels, are the most common targets, closely reflecting the current treatment landscape of these diseases.

The report, Behavioral Disorders Drug Development Pipeline Review, 2017 provides an overview of the behavioral disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.

Scope

  • Which companies are the most active within the pipeline for behavioral disorder therapeutics?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in the field of behavioral disorders?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Behavioral Disorders Report Coverage
    • Autism - Overview
    • Obsessive-Compulsive Disorder - Overview
    • Attention Deficit Hyperactivity Disorder (ADHD) - Overview
  • Therapeutics Development
    • Autism
      • Pipeline Overview
        • Table figure 1: Number of Products under Development for Autism
        • Table Number of Products under Development for Autism
      • Pipeline by Companies
        • Table figure 2: Number of Products under Development by Companies, Autism
        • Table Number of Products under Development by Companies, Autism
      • Pipeline by Universities/Institutes
        • Table figure 3: Number of Products under Development by Universities/Institutes, Autism
        • Table Number of Products under Development by Universities/Institutes, Autism
      • Products under Development by Companies
        • Table Products under Development by Companies, Autism
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Autism
    • Obsessive-Compulsive Disorder
      • Pipeline Overview
        • Table figure 4: Number of Products under Development for Obsessive-Compulsive Disorder
        • Table Number of Products under Development for Obsessive-Compulsive Disorder
      • Pipeline by Companies
        • Table figure 5: Number of Products under Development by Companies, Obsessive-Compulsive Disorder
        • Table Number of Products under Development by Companies, Obsessive-Compulsive Disorder
      • Products under Development by Companies
        • Table Products under Development by Companies, Obsessive-Compulsive Disorder
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Pipeline Overview
        • Table figure 6: Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD)
      • Pipeline by Companies
        • Table figure 7: Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
      • Pipeline by Universities/Institutes
        • Table figure 8: Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
      • Products under Development by Companies
        • Table Products under Development by Companies, Attention Deficit Hyperactivity Disorder (ADHD)
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Attention Deficit Hyperactivity Disorder (ADHD)
  • Therapeutics Assessment
    • Autism
      • Assessment by Target
        • Table figure 9: Number of Products by Top 10 Targets, Autism
        • Table figure 10: Number of Products by Stage and Top 10 Targets, Autism
        • Table Number of Products by Stage and Target, Autism
      • Assessment by Mechanism of Action
        • Table figure 11: Number of Products by Top 10 Mechanism of Actions, Autism
        • Table figure 12: Number of Products by Stage and Top 10 Mechanism of Actions, Autism
        • Table Number of Products by Stage and Mechanism of Action, Autism
      • Assessment by Route of Administration
        • Table figure 13: Number of Products by Routes of Administration, Autism
        • Table figure 14: Number of Products by Stage and Routes of Administration, Autism
        • Table Number of Products by Stage and Route of Administration, Autism
      • Assessment by Molecule Type
        • Table figure 15: Number of Products by Molecule Types, Autism
        • Table figure 16: Number of Products by Stage and Molecule Types, Autism
        • Table Number of Products by Stage and Molecule Type, Autism
    • Obsessive-Compulsive Disorder
      • Assessment by Target
        • Table figure 17: Number of Products by Targets, Obsessive-Compulsive Disorder
        • Table figure 18: Number of Products by Stage and Targets, Obsessive-Compulsive Disorder
        • Table Number of Products by Stage and Target, Obsessive-Compulsive Disorder
      • Assessment by Mechanism of Action
        • Table figure 19: Number of Products by Mechanism of Actions, Obsessive-Compulsive Disorder
        • Table figure 20: Number of Products by Stage and Mechanism of Actions, Obsessive-Compulsive Disorder
        • Table Number of Products by Stage and Mechanism of Action, Obsessive-Compulsive Disorder
      • Assessment by Route of Administration
        • Table figure 21: Number of Products by Stage and Routes of Administration, Obsessive-Compulsive Disorder
        • Table Number of Products by Stage and Route of Administration, Obsessive-Compulsive Disorder
      • Assessment by Molecule Type
        • Table figure 22: Number of Products by Stage and Molecule Types, Obsessive-Compulsive Disorder
        • Table Number of Products by Stage and Molecule Type, Obsessive-Compulsive Disorder
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Assessment by Target
        • Table figure 23: Number of Products by Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table figure 24: Number of Products by Stage and Top 10 Targets, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products by Stage and Target, Attention Deficit Hyperactivity Disorder (ADHD)
      • Assessment by Mechanism of Action
        • Table figure 25: Number of Products by Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table figure 26: Number of Products by Stage and Top 10 Mechanism of Actions, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products by Stage and Mechanism of Action, Attention Deficit Hyperactivity Disorder (ADHD)
      • Assessment by Route of Administration
        • Table figure 27: Number of Products by Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table figure 28: Number of Products by Stage and Routes of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products by Stage and Route of Administration, Attention Deficit Hyperactivity Disorder (ADHD)
      • Assessment by Molecule Type
        • Table figure 29: Number of Products by Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table figure 30: Number of Products by Stage and Molecule Types, Attention Deficit Hyperactivity Disorder (ADHD)
        • Table Number of Products by Stage and Molecule Type, Attention Deficit Hyperactivity Disorder (ADHD)
  • Companies Involved in Therapeutics Development
    • Autism
      • 4D Pharma PLC
        • Table Autism - Pipeline by 4D Pharma PLC
      • Addex Therapeutics Ltd
        • Table Autism - Pipeline by Addex Therapeutics Ltd
      • Aequus Pharmaceuticals Inc
        • Table Autism - Pipeline by Aequus Pharmaceuticals Inc
      • Aevi Genomic Medicine Inc
        • Table Autism - Pipeline by Aevi Genomic Medicine Inc
      • AgeneBio Inc
        • Table Autism - Pipeline by AgeneBio Inc
      • Anima Biotech Ltd
        • Table Autism - Pipeline by Anima Biotech Ltd
      • APeT Holding BV
        • Table Autism - Pipeline by APeT Holding BV
      • BioCrea GmbH
        • Table Autism - Pipeline by BioCrea GmbH
      • BioHealthonomics Inc
        • Table Autism - Pipeline by BioHealthonomics Inc
      • BrainStorm Cell Therapeutics Inc
        • Table Autism - Pipeline by BrainStorm Cell Therapeutics Inc
      • Confluence Pharmaceuticals LLC
        • Table Autism - Pipeline by Confluence Pharmaceuticals LLC
      • Coronis NeuroSciences Ltd
        • Table Autism - Pipeline by Coronis NeuroSciences Ltd
      • Curemark LLC
        • Table Autism - Pipeline by Curemark LLC
      • DRI Biosciences Corp
        • Table Autism - Pipeline by DRI Biosciences Corp
      • F. Hoffmann-La Roche Ltd
        • Table Autism - Pipeline by F. Hoffmann-La Roche Ltd
      • GW Pharmaceuticals Plc
        • Table Autism - Pipeline by GW Pharmaceuticals Plc
      • Heptares Therapeutics Ltd
        • Table Autism - Pipeline by Heptares Therapeutics Ltd
      • Immuron Ltd
        • Table Autism - Pipeline by Immuron Ltd
      • Intra-Cellular Therapies Inc
        • Table Autism - Pipeline by Intra-Cellular Therapies Inc
      • Leading BioSciences Inc
        • Table Autism - Pipeline by Leading BioSciences Inc
      • MedDay SA
        • Table Autism - Pipeline by MedDay SA
      • Omeros Corp
        • Table Autism - Pipeline by Omeros Corp
      • OptiNose US Inc
        • Table Autism - Pipeline by OptiNose US Inc
      • Ovensa Inc
        • Table Autism - Pipeline by Ovensa Inc
      • Q BioMed Inc
        • Table Autism - Pipeline by Q BioMed Inc
      • Sumitomo Dainippon Pharma Co Ltd
        • Table Autism - Pipeline by Sumitomo Dainippon Pharma Co Ltd
    • Obsessive-Compulsive Disorder
      • AbbVie Inc
        • Table Obsessive-Compulsive Disorder - Pipeline by AbbVie Inc
      • Addex Therapeutics Ltd
        • Table Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd
      • Amorsa Therapeutics Inc
        • Table Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc
      • Omeros Corp
        • Table Obsessive-Compulsive Disorder - Pipeline by Omeros Corp
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • 4P-Pharma SAS
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by 4P-Pharma SAS
      • Aevi Genomic Medicine Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Aevi Genomic Medicine Inc
      • Alcobra Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Alcobra Ltd
      • Amarantus Bioscience Holdings Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Amarantus Bioscience
      • APeT Holding BV
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by APeT Holding BV
      • BCWorld Pharm Co Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BCWorld Pharm Co Ltd
      • BioHealthonomics Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by BioHealthonomics Inc
      • Cingulate Therapeutics LLC
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Cingulate Therapeutics LLC
      • Collegium Pharmaceutical Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Collegium Pharmaceutical Inc
      • Curemark LLC
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Curemark LLC
      • DURECT Corp
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by DURECT Corp
      • Eli Lilly and Company
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Eli Lilly and Company
      • H. Lundbeck A/S
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by H. Lundbeck A/S
      • Heptares Therapeutics Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Heptares Therapeutics Ltd
      • Highland Therapeutics Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Highland Therapeutics Inc
      • KemPharm Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by KemPharm Inc
      • Luc Therapeutics Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Luc Therapeutics Inc
      • Merck & Co Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Merck & Co Inc
      • Neos Therapeutics Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Neos Therapeutics Inc
      • NeuroDerm Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by NeuroDerm Ltd
      • Novartis AG
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Novartis AG
      • Noven Pharmaceuticals Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Noven Pharmaceuticals Inc
      • Otsuka Pharmaceutical Co Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Otsuka Pharmaceutical Co Ltd
      • P2D Bioscience
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by P2D Bioscience
      • Reviva Pharmaceuticals Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Reviva Pharmaceuticals Inc
      • Shire Plc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Shire Plc
      • SK Biopharmaceuticals Co Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by SK Biopharmaceuticals Co Ltd
      • Sunovion Pharmaceuticals Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Sunovion Pharmaceuticals Inc
      • Supernus Pharmaceuticals Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Supernus Pharmaceuticals Inc
      • Taisho Pharmaceutical Holdings Co Ltd
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Taisho Pharmaceutical
      • Tris Pharma Inc
        • Table Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline by Tris Pharma Inc
  • Dormant Projects
    • Autism
      • Table Autism - Dormant Projects
    • Obsessive-Compulsive Disorder
      • Table Obsessive-Compulsive Disorder - Dormant Projects
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects
  • Discontinued Products
    • Autism
      • Table Autism - Discontinued Products
    • Obsessive-Compulsive Disorder
      • Table Obsessive-Compulsive Disorder - Discontinued Products
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Table Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products
  • Product Development Milestones
    • Autism
      • Featured News & Press Releases
    • Obsessive-Compulsive Disorder
      • Featured News & Press Releases
    • Attention Deficit Hyperactivity Disorder (ADHD)
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report